No more talk of Peptidream. Sights are firmly fixed onto Sarepta and the CPPs used in their PPMO research. The PPMO work has created a lot of excitement in the US and due in-part to this, Sarepta's sp is flying high.
In today's up-date PYC's CEO writes in context to Sarepta's developments: "The opportunity for Phylogica is to clearly demonstrate the competitive advantage of our CPPs...".
On page 1. CEO writes: "Phylogica has a real near-term opportunity to demonstrate a competitive advantage by showing head to head out-performance of the current delivery approach for cargoes of interest..."
As I read it: PYC will be testing their CPP against Sarepta's. Both CPPs attached to the same type of drug molecule (relevant ASO) so they are tested head to head. Bring it on.
PYC Price at posting:
3.1¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)